Patents by Inventor Roland M. Williams

Roland M. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240131128
    Abstract: Embodiments of the disclosure are related to a method of treating cancer including preventative treatment comprising administering nitrous oxide and oxygen and B-12 and/or folic acid to the patient, and/or administering a botulinum toxin to the patient by injection, wherein the latter is directed to preventative treatment.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 25, 2024
    Inventor: Roland M. Williams
  • Patent number: 11925677
    Abstract: A method for treating chronic pancreatitis and diabetes type II in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: March 12, 2024
    Assignee: Penland Foundation
    Inventor: Roland M. Williams
  • Patent number: 11883473
    Abstract: A method for treating dyslexia or reading developmental disorder (RDD) in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. In infants or toddlers—from about birth to 5 years old, botulinum toxin is used to prevent or minimize damage to the developing brain that would result in dyslexia; in older children and adult patients with dyslexia, botulinum toxin will be used to reduce or eliminate their symptoms.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: January 30, 2024
    Assignee: PENLAND FOUNDATION
    Inventor: Roland M. Williams
  • Publication number: 20230405083
    Abstract: A method of treating vertigo in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient.
    Type: Application
    Filed: August 28, 2023
    Publication date: December 21, 2023
    Inventor: Roland M. Williams
  • Patent number: 11744881
    Abstract: A method for treating Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. The administration of the botulinum toxin prevents an overproduction of glutamate, Substance P, and CGRP in a sensory system and thereby inhibits a migration of the glutamate, Substance P, and CGRP to the motor system, which otherwise would cause neuroexcitatory toxicity that results in the death of motor neurons.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: September 5, 2023
    Assignee: PENLAND FOUNDATION
    Inventor: Roland M. Williams
  • Patent number: 11738071
    Abstract: A method for treating chronic kidney disease, or other renal conditions that has resulted in chronic low-grade activation of the cytokine system in a patient that is in need. Thereof comprising administering botulinum toxin to mitigate the inflammatory state in the kidney. A method of treating acute kidney disease that has resulted from an acute activation of the cytokine system in a patient in need thereof comprising administering nitrous oxide or any inhaled anesthetic in amounts, concentrations, and durations needed to control cytokines and mitigate further damage to healthy kidney tissue.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: August 29, 2023
    Assignee: Penland Foundation
    Inventor: Roland M. Williams
  • Publication number: 20230077154
    Abstract: Botulinum toxin for use in treating cirrhosis in a patient in need thereof is provided. The treatment comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof of the patient.
    Type: Application
    Filed: November 15, 2022
    Publication date: March 9, 2023
    Inventor: Roland M. Williams
  • Publication number: 20230070332
    Abstract: Botulinum toxin for use in treating arrhythmia in a patient in need thereof is provided. The treatment comprises administering botulinum toxin to the patient. Botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient.
    Type: Application
    Filed: November 15, 2022
    Publication date: March 9, 2023
    Inventor: Roland M. Williams
  • Publication number: 20230071563
    Abstract: Botulinum toxin for use in treating chronic obstructive pulmonary disease (COPD) in a patient in need thereof is provided. The treatment comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient.
    Type: Application
    Filed: November 15, 2022
    Publication date: March 9, 2023
    Inventor: Roland M. Williams
  • Publication number: 20230071295
    Abstract: Botulinum toxin for use in treating asthma in a patient in need thereof is provided. The treatment comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof of the patient.
    Type: Application
    Filed: November 15, 2022
    Publication date: March 9, 2023
    Inventor: Roland M. Williams
  • Publication number: 20230011705
    Abstract: A method for treating chronic pancreatitis and diabetes type II in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 12, 2023
    Inventor: Roland M. Williams
  • Publication number: 20230012181
    Abstract: A method for treating chronic kidney disease, or other renal conditions that has resulted in chronic low-grade activation of the cytokine system in a patient that is in need. Thereof comprising administering botulinum toxin to mitigate the inflammatory state in the kidney. A method of treating acute kidney disease that has resulted from an acute activation of the cytokine system in a patient in need thereof comprising administering nitrous oxide or any inhaled anesthetic in amounts, concentrations, and durations needed to control cytokines and mitigate further damage to healthy kidney tissue.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 12, 2023
    Inventor: Roland M. Williams
  • Publication number: 20230009875
    Abstract: Embodiments of the disclosure are related to a method of treating cancer including preventative treatment comprising administering nitrous oxide and oxygen to the patient by inhalation, and/or administering a botulinum toxin to the patient by injection, wherein the latter is directed to preventative treatment.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 12, 2023
    Inventor: Roland M. Williams
  • Publication number: 20220378885
    Abstract: A method of treating ASD (autism) in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. In infants or toddlers—from about 1 to 5 year old, it is used to prevent or minimize damage to the developing brain; in older children and adult Autism Spectrum Disorder (ASD) patients, it will be used to reduce or eliminate their symptoms.
    Type: Application
    Filed: August 4, 2022
    Publication date: December 1, 2022
    Inventor: Roland M. Williams
  • Publication number: 20220362286
    Abstract: Nitrous oxide and oxygen for use in treating ARDS caused by viral and bacterial infections, injuries, or other conditions that have resulted in acute, excess activation of the cytokine system in a patient in need thereof is provided. The treatment comprises administering nitrous oxide and oxygen to the patient by inhalation before, during, and/or after ARDS occurs. It is also applicable for treating, alleviating, and/or preventing an aftereffect of said conditions. A composition, duration, an interval, and a total amount of nitrous oxide and oxygen depend on each patient's individual situation and needs. Inhalation of nitrous oxide and oxygen can also stop the post ARDS symptoms that remain after an acute ARDS condition such as, but not limited to viral infections, bacterial infections, injuries, or any condition that results from any cytokine storm. Inhalation of nitrous oxide and oxygen can also treat local cytokine damages caused by said conditions.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 17, 2022
    Inventor: Roland M. Williams
  • Patent number: 11439694
    Abstract: A method of treating ASD (autism) in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. In infants or toddlers—from about 1 to 5 year old, it is used to prevent or minimize damage to the developing brain; in older children and adult Autism Spectrum Disorder (ASD) patients, it will be used to reduce or eliminate their symptoms.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 13, 2022
    Assignee: Penland Foundation
    Inventor: Roland M. Williams
  • Publication number: 20220118066
    Abstract: A method of treating ASD (autism) in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. In infants or toddlers—from about 1 to 5 year old, it is used to prevent or minimize damage to the developing brain; in older children and adult Autism Spectrum Disorder (ASD) patients, it will be used to reduce or eliminate their symptoms.
    Type: Application
    Filed: November 12, 2021
    Publication date: April 21, 2022
    Inventor: Roland M. Williams
  • Patent number: 11241479
    Abstract: A method of tolerance to narcotics in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F and botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, and a combination thereof. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. The therapeutically effective amount of the botulinum toxin administered is between about 1 unit and about 150 units.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: February 8, 2022
    Assignee: Penland Foundation
    Inventor: Roland M. Williams
  • Publication number: 20210299231
    Abstract: A method for treating Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. The administration of the botulinum toxin prevents an overproduction of glutamate, Substance P, and CGRP in a sensory system and thereby inhibits a migration of the glutamate, Substance P, and CGRP to the motor system, which otherwise would cause neuroexcitatory toxicity that results in the death of motor neurons.
    Type: Application
    Filed: March 29, 2021
    Publication date: September 30, 2021
    Inventor: Roland M. Williams
  • Patent number: 11090371
    Abstract: A method for treating cirrhosis in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof of the patient.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: August 17, 2021
    Assignee: PENLAND FOUNDATION
    Inventor: Roland M. Williams